


Diastereoselective Synthesis of 2-Arylmethylene-6-hydroxyspiro[4.5]deca-7-ones via FeCl₃·6H₂O-Catalyzed Spiroannulation/Hydride Transfer of 6-(5-Arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols

Hsin-Hui Lin, Kuan-Yi Lee, Yin-An Chen, Chi-Fan Liu, and Ming-Chang P. Yeh*

Department of Chemistry, National Taiwan Normal University, 88 Ding-Jou Road, Section 4, Taipei 11677, Taiwan, Republic of China

S Supporting Information



ABSTRACT: In the presence of a catalytic amount of FeCl₃·6H₂O, 6-(5-arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols underwent attack of the pendant acetylene at the iron-activated oxirane to give a vinylic carbocation. Hydride transfer from the carbinol carbon to the newly formed cation center furnished 2-arylmethylene-6-hydroxyspiro[4.5]deca-7-ones in excellent stereoselectivity and good yields.

The spirocyclic skeleton is present in many natural products. Due to the existence of spirocycles possessing useful biological properties, the development of effective methods to all carbon spirocycles has been actively pursued.¹ Many synthetic methods for the construction of such spirocycles involved alkylation via direct substitution² or Michael addition,³ base-induced vinylcyclo-propanol and -butanol rearrangement,⁴ pinacol-type rearrangement of cyclic allylic alcohols bearing an aldehyde,⁵ or cyclic 2,3-epoxyols,⁶ rearrangement of bridged cycles,⁷ Nazarov-type spiroannulation of dienones,⁸ Diels–Alder cycloaddition of dienes and cyclic enones,⁹ transition-metal-based cycloaddition,¹⁰ ene reaction,¹¹ radical cyclization,¹² and ring closing metathesis of *gem*-dialkenyl molecules.¹³ As part of our ongoing investigations on Lewis acid assisted cyclization of cyclic enynols, we recently reported an example of TfOH-catalyzed cycloisomerization of C-3-arylpropargylsulfonamide-tethered 2,3-epoxycyclohexanols at 50 °C in dichloroethane (DCE) for 40 min, producing spiro piperidines in good yields (Scheme 1, eq 1).¹⁴ The reaction started with the TfOH-assisted semipinacol rearrangement to give the ring contraction 2-arylpropargylsulfonamide-tethered cyclopentanecarbaldehyde, which underwent a TfOH-promoted alkyne-aldehyde metathesis via [2 + 2] cycloaddition/[2 + 2] cycloreversion to furnish the spiro piperidines. Surprisingly, when the *N*-tosylpropargyl tether was replaced by an alkynylalkyl group, the Lewis acid catalyzed cycloisomerization reaction of alkynylalkyl-tethered 2,3-epoxycyclohexanols proceeded via a different reaction path (Scheme 1, eq 2). Although intramolecular coupling reaction of alkynes and epoxides has been studied, the reaction required NiBr₂·3H₂O, PhMe₂P, and reducing agent *i*-PrOH at 60 °C.¹⁵ Herein, we

report a FeCl₃·6H₂O-catalyzed spiroannulation/hydride transfer of 6-alkynylalkyl-tethered 7-oxabicyclo[4.1.0]-heptan-2-ols, affording 2-arylmethylene-6-hydroxyspiro[4.5]deca-7-ones in good yields and excellent stereoselectivity under air at room temperature. The spiroannulation may start from attack of the acetylene at the FeCl₃·6H₂O-activated oxirane to form a carbocation, followed by intramolecular hydride transfer from the carbinol carbon to the newly formed cation center, which furnished 2-arylmethylene-6-hydroxyspiro[4.5]deca-7-ones.


The cyclic *syn* epoxy alcohols **1** tethering a 5-arylpent-4-ynyl moiety at the C-6 position of the ring were prepared from epoxidation of the corresponding 3-(5-arylpent-4-yn-1-yl)-cyclohex-2-enols¹⁶ with 1.2 equiv of *m*-chloroperoxybenzoic acid (*m*-CPBA). To select an optimum reaction protocol for the cycloisomerization of **1a**, various parameters, such as Brønsted and Lewis acids, solvents, and temperatures, were investigated. With acids such as HOTf and ZnBr₂ in DCM, **1a** decomposed to give an unidentified crude mixture (Table 1, entries 1 and 2). When reacted with 0.1 equiv of BF₃·OEt₂ in DCM (0.1 M) at room temperature under air for 10 min, **1a** generated the α -hydroxy spirocyclic ketone **2a** as a single stereoisomer in 27% yield (Table 1, entry 3), and none of the semipinacol rearrangement product was obtained. NMR studies have provided the initial evidence for the structural assignment of **2a**. The ¹H NMR spectrum of **2a** showed a triplet, centered at δ 6.41, assigned to the vinyl proton; a doublet of doublets, centered at δ 4.39, assigned to the proton at the carbinol carbon; and a doublet, centered at δ 3.60, assigned to the

Received: October 11, 2014


Published: November 14, 2014

Scheme 1. Acid-Catalyzed Cycloisomerization Reaction of C-6-Alkynylalkyl-Tethered 7-Oxabicyclo[4.1.0]heptan-2-ols

Previous work:



This work:

Table 1. Optimization of the Reaction Conditions^a

entry	Lewis acid	equiv	solvent	time	yield (%)
1	TfOH	0.1	0.2 M DCM	0.5 h	n.d. ^b
2	ZnBr ₂	0.5	0.1 M DCM	26 h	n.d. ^b
3	BF ₃ ·OEt ₂	0.1	0.1 M DCM	10 min	27
4	FeCl ₃	0.5	0.1 M DCM	0.5 h	37
5	FeCl ₃	2.0	0.1 M DCM	0.5 h	21
6	FeCl ₃	0.3	0.1 M THF	4.0 h	trace
7	FeCl ₃	0.5	0.1 M DBE	24 h	trace
8	FeCl ₃	0.5	0.1 M DCE	3.0 h	31
9	FeCl ₃ ·6H ₂ O	0.1	0.1 M DCM	3.0 h	31
10	FeCl ₃ ·6H ₂ O	0.3	0.01 M DCM	1.0 h	50
11	FeCl ₃ ·6H ₂ O	0.1	0.01 M DCM	3.5 h	57
12	FeCl ₃ ·6H ₂ O	0.1	0.01 M THF	24 h	n.r. ^c
13	FeCl ₃ ·6H ₂ O	0.1	0.01 M MeCN	24 h	n.r. ^c
14	AuCl(PPh ₃)/AgOTf	0.05	0.1 M DCM	3 min	8
15	InCl ₃	0.5	0.1 M DCM	22 h	21
16	AgOTf	0.1	0.1 M DCM	4.0 h	5
17	SnCl ₄	0.5	0.1 M DCM	3.0 h	29
18	TMSCl	0.3	0.1 M DCM	2.0 h	10
19	Fe(NO ₃) ₃ ·9H ₂ O	0.1	0.01 M DCM	25 h	n.r. ^c


^aAll reactions were carried out under air at room temperature. ^bNot detected. ^cNo reaction.

hydroxyl proton. The ¹³C NMR spectrum exhibited a signal at δ 211.1 assigned to the carbonyl carbon; a signal at δ 150.8 assigned to the olefinic quaternary carbon; a signal at δ 126.2 assigned to the other olefinic carbon; and a signal at δ 81.3 assigned to the carbinol carbon. The relative stereochemistry of **2a** was proved by NOESY (nuclear Overhauser enhancement spectroscopy) measurements and further secured by X-ray diffraction analysis.¹⁷

Next, we focused our efforts toward the use of other Lewis acids (SnCl₄, AuCl(PPh₃)/AgOTf, InCl₃, SnCl₄, AgOTf, TMSCl, FeCl₃, and FeCl₃·6H₂O), solvents (DCM, DCE, DBE, THF, MeCN, and MeOH), and temperatures. Results of the study are summarized in Table 1. As can be seen from Table 1, subsection of 0.1 equiv of FeCl₃·6H₂O to **1a** in DCM at 0.01 M concentration under air at room temperature for 3.5 h produced **2a** in a best isolated yield of 57% (Table 1, entry 11).

With optimized reaction conditions in hand, we next explored the generality of the spiroannulation/hydride transfer reaction conditions with various substituents on the phenyl ring, and results are shown in Table 2. The phenyl rings bearing one or two methyl groups at the C-3 or C-4 position of the phenyl ring, **2b–d**, were smoothly cyclized to give the desired spirocyclic ketones **2b–d** in 70–80% yields. A phenyl group at the C-4 position of the phenyl group, **1e**, was also efficient, providing a 77% yield of the desired spirocyclic ketone **2e**.¹⁷ Sterically hindered naphthalenyl- or phenanthrenyl-substituted alkynes, **1f** and **1g**, resulted in lower yields of the corresponding products **2f** (46%) and **2g** (45%). Substrate **1h**, with an electron-donating methoxy group at C-3 of the phenyl ring, afforded **2h**¹⁷ in 59% yield. Moving this electron-donating group to C-4, **1i** gave a significant increase in the yield of the desired product **2i** (86%). On the basis of higher yields obtained with a methyl or methoxy group at C-4 of the phenyl


Table 2. Synthesis of 2-Arylmethylene-6-hydroxyspiro[4.5]deca-7-ones from 6-(5-Arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols and $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ ^{a,b,c}



^aReaction conditions: 1 (1.0 equiv), $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ (10 mol %), air, room temperature. ^bStructures were confirmed by X-ray diffraction analysis. ^cNo reaction.


ring, it may be stated that an electron-donating substituent at the C-4 of the phenyl ring increased the nucleophilicity of the acetylene, which attacked at the iron-activated oxirane more efficiently to give a higher yield of the spirocyclic ketone (see Scheme 2). Moreover, the presence of a bromine atom on the phenyl ring, for example, **1j** and **1k**, was also tolerated and produced the corresponding spirocyclic ketones **2j** and **2k**, albeit in only 13 and 17% yield, respectively. Incorporation of

an arylalkynyl moiety at the C-4 position of the phenyl ring, **1l–n**, was also effective and generated the desired spirocyclic ketones **2l–n** in moderate yields (46–62%). Unfortunately, compound **1o** bearing an electron-withdrawing ester group at the C-3 position of the phenyl ring delivered the spirocyclic ketone **2o** in only 10% yield. Moreover, compound **1p**, carrying an amino group at C-4 of the phenyl ring, was recovered

Scheme 2. Suggested Reaction Mechanism for the Formation of **1** to **2**


quantitatively when treated with $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ under the standard reaction conditions.

The reaction path for the formation of **2a** from **1a** is suggested in Scheme 2. Attack of the pendant acetylene at the iron-activated oxirane **7** gave the vinylic cation **8**. Transfer of the hydride from the carbinol carbon to the proximal cation center led to the spirocyclic ketone **2** after protonation. A similar 1,5-hydride shift in a vinylic cation intermediate has been reported.¹⁸ Moreover, treatment of the diastereomer of **1i**, *anti*-**1i** (Figure 1), with 0.1 equiv of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ resulted in

Figure 1. Structure of *anti*-**1i**.

recovering of the starting substrate quantitatively under the standard reaction conditions. Therefore, it is reasonable to state that chelation of both hydroxyl and oxirane oxygens to the iron center to form intermediates **7** and **8** is critical for the spiroannulation/hydride transfer reaction path. It is important to note that the electron-withdrawing effect of the *N*-tosyl


Scheme 3. Deuterium-Labeling Study



group in the alkynylalkyl tether (Scheme 1, eq 1) may reduce the nucleophilicity of the acetylene, and thereby prevented the acetylene from attacking the activated oxirane. Instead, the reaction underwent the acid-promoted semipinacol rearrangement/alkyne-aldehyde metathesis to afford the spiro-piperidines.


To provide further insight into the reaction mechanism, a deuterium-labeling experiment was conducted. The deuterated substrate **1c-d**, with 86% *d*-incorporation (relative to one proton) at the carbinol carbon, was subjected to the optimized reaction conditions (Scheme 3). The desired compound **2c-d** was isolated in 81% yield with 86% *d*-incorporation at the vinylic carbon. Moreover, the deuterium NMR of **2c-d** verified the existence of deuterium incorporation at the vinylic position (see the NMR spectra in the Supporting Information for details). Thus, the deuterium-labeling study provided strong evidence to support the hydride transfer mechanism, as suggested above.

However, no desired spiro hydroxyketone was observed when substrate **9**, having a terminal alkyne, was treated with 0.1 equiv of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ under the same reaction conditions. Instead, carbochlorination of **9** occurred,¹⁶ generating 8-chlorospiro[5.5]undec-7-ene-1,2-diol (**10**)¹⁷ as a single stereoisomer in 34% yield (Scheme 4). Compound **9** failed to

Scheme 4. Carbochlorination of **9**

undergo the usual spiroannulation/hydride transfer process, which may be due to the unfavorable formation of a terminal vinylic carbocation. Unfortunately, the use of 1.0 equiv of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ did not improve the yield, and **9** gave **10** in only 23% yield. Moreover, subjection of the methyl-terminated alkyne substrate, **11**, to $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ under the standard reaction conditions led to a 24% yield of the spirodiol **12** and a 20% yield of the desired spirocyclic ketone **13** (Scheme 5). The formation of **12** may start from attack of the acetylene

Scheme 5. Cycloisomerization of 11



at the iron-activated oxirane to form the cation intermediate 14. Deprotonation of the methyl group gave the spiroallene 15, which underwent double bond migration to afford the spirodiendiol 12. The (*Z*)-configuration of the exo double bond was confirmed by NOSEY NMR spectroscopy.

In conclusion, this report describes a general stereoselective synthesis of 2-arylmethylene-6-hydroxyspiro[4.5]deca-7-ones through $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ -catalyzed spiroannulation/hydride transfer of 6-(5-arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols. A variety of spiro α -hydroxyketones were available stereoselectively using a catalytic amount of the inexpensive, efficient, and environmentally friendly $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ at room temperature in the open air.

EXPERIMENTAL SECTION

General Considerations. All $\text{FeCl}_3 \cdot \text{H}_2\text{O}$ -catalyzed cycloisomerization reactions were performed in the open air at ambient temperature. Anhydrous solvents or reaction mixtures were transferred via an oven-dried syringe or cannula. Solvents were predried by molecular sieves and then by passing through an Al_2O_3 column. 6-(5-Arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols 1 were synthesized by oxidation of 6-(5-arylpent-4-yn)cyclohex-2-enol¹⁵ with MCPBA. Column chromatography was conducted with silica gel 60, hexanes, and ethyl acetate. ^1H NMR were recorded at 400 or 500 MHz in CDCl_3 with CHCl_3 (δ 7.24 ppm) or $(\text{CH}_3)_4\text{Si}$ (δ 0.00 ppm) as internal standard. ^{13}C NMR spectra were obtained at 100 or 125 MHz in CDCl_3 with CHCl_3 as internal standard (δ 77.00 ppm). Melting points are uncorrected. Mass spectra were acquired on a spectrometer at an ionization potential of 70 eV and were reported as mass/charge (*m/e*) with percent relative abundance. High-resolution mass spectra were obtained with a double-focusing mass spectrometer.

General Procedure for the Synthesis of 1a. To a solution of *t*-butyllithium (15 mmol, 1.6 M in pentane) was added slowly a solution of (5-iodopent-1-yn-1-yl)benzene (2.538 g, 9.4 mmol) in ether (20 mL) over a period of 30 min at -78°C under N_2 . After the reaction mixture was stirring at this temperature for 30 min, 3-ethoxycyclohex-2-en-1-one (1.10 g, 7.85 mmol) in ether (15 mL) was added dropwise at -78°C under N_2 . After 0.5 h, the reaction mixture was allowed to warm to room temperature. The reaction was monitored by TLC, until no trace of enone could be detected. The mixture was quenched with $\text{HCl}_{(\text{aq})}$ (35 mL, 2.0 M) at 0°C for 30 min, followed by stirring at rt for 2 h. The aqueous phase was extracted with ether (3 \times 30 mL) and washed with brine (30 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated under reduced pressure to give a crude oil. The oil was purified by flash column over silica gel

(3 \times 13 cm, 10% ethyl acetate/hexanes) to afford 3-(5-phenylpent-4-yn-1-yl)cyclohex-2-enone as a light yellow oil (1.220 g, 66%). To a solution of 3-(5-phenylpent-4-yn-1-yl)cyclohex-2-enone (0.370 g, 1.55 mmol) in methanol (15.5 mL) were added NaBH_4 (0.070 g, 1.80 mmol) and $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (0.870 g, 2.32 mmol) at 0°C under air. After the reaction was stirred at room temperature for 30 min, the methanol was removed under reduced pressure. To the reaction mixture was added water and ethyl acetate (1/1). The aqueous phase was extracted with ethyl acetate (3 \times 30 mL) and washed with brine (30 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated under reduced pressure to give a crude oil. To the crude product in DCM (15.5 mL) at 0°C was added *m*CPBA (0.395 g, 2.33 mmol, 70%) portionwise, and the reaction mixture was stirred at 0°C for 10 min. The reaction mixture was allowed to warm up to room temperature. After being stirred for 3 h, the mixture was quenched with saturated NaHCO_3 (aq). The resulting mixture was stirred at rt for 30 min. The mixture was extracted with DCM (3 \times 30 mL) and washed with brine. The organic layer was dried over MgSO_4 . The drying agent was removed by filtration, and the resulting solution was concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel (3 \times 13 cm, 10% ethyl acetate/hexanes), providing (1*S**,2*S**,6*R**)-6-(5-phenylpent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (1a) (0.278 g, 1.09 mmol, 70%) as a yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 7.39–7.31 (m, 2H), 7.28–7.26 (m, 3H), 4.00 (s, 1H), 3.19 (d, *J* = 2.9 Hz, 1H), 2.45–2.43 (m, 2H), 1.99 (s, 1H), 1.88–1.81 (m, 1H), 1.76–1.68 (m, 5H), 1.58–1.43 (m, 3H), 1.30–1.22 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 131.5, 128.2, 127.6, 29.4, 81.2, 66.8, 63.9, 61.2, 36.5, 29.2, 26.8, 24.0, 19.4, 18.1; IR (CH_2Cl_2) 3412, 2942, 2856, 1491, 1442, 848, 758, 693 cm^{-1} ; MS (EI) *m/e* (%) 256.1 ($[\text{M}]^+$, 8), 238.1 (31), 210.1 (22), 128.1 (100), 115.1 (70); HRMS (EI) *m/e* calcd for $\text{C}_{17}\text{H}_{20}\text{O}_2$ $[\text{M}]^+$ 256.1463, found 256.1466.

(1*S**,2*S**,6*R**)-6-(5-*m*-Tolylpent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (1b). (0.561 g, 0.21 mmol, 81% from 0.821 g, 3.26 mmol of 3-(5-(*m*-tolyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 7.21–7.15 (m, 3H), 7.08 (d, *J* = 6.9 Hz, 1H), 4.01–3.98 (m, 1H), 3.19 (d, *J* = 3.1 Hz, 1H), 2.44–2.41 (m, 2H), 2.31 (s, 3H), 2.08 (br s, 1H), 1.87–1.80 (m, 1H), 1.75–1.67 (m, 5H), 1.58–1.42 (m, 3H), 1.30–1.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 137.9, 132.2, 128.6, 128.6, 128.1, 123.6, 89.0, 81.3, 66.9, 64.0, 61.3, 36.6, 29.1, 26.8, 24.0, 21.2, 19.4, 18.2; IR (CH_2Cl_2) 3421, 2940, 2864, 1715, 1600, 1448, 784, 692 cm^{-1} ; MS (ESI) *m/e* (%) 293.1 ($[\text{M} + \text{Na}]^+$, 100), 288.2 (18); HRMS (ESI) *m/e* calcd for $\text{C}_{18}\text{H}_{22}\text{NaO}_2$ $[\text{M} + \text{Na}]^+$ 293.1517, found 293.1519.

(1*S**,2*S**,6*R**)-6-(5-*p*-Tolylpent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (1c-d). (0.662 g, 2.45 mmol, 67% from 0.920 g, 3.66 mmol of 3-(5-(*p*-tolyl)pent-4-yn-1-yl)cyclohex-2-enone). A colorless oil: ^1H NMR (400 MHz, CDCl_3) δ 7.27 (d, *J* = 7.9 Hz, 2H), 7.08 (d, *J* = 7.9 Hz, 2H), 3.99 (br s, 1H), 3.18 (d, *J* = 3.0 Hz, 1H), 2.44–2.41 (m, 2H), 2.33 (s, 3H), 2.04 (d, *J* = 8.3 Hz, 1H), 1.87–1.80 (m, 1H), 1.75–1.67 (m, 5H), 1.59–1.42 (m, 3H), 1.30–1.21 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 137.6, 131.4, 128.9, 120.7, 88.5, 81.2, 66.8, 63.6, 61.2, 36.5, 29.1, 26.8, 24.0, 21.4, 19.4, 18.1; IR (CH_2Cl_2) 3419, 2942, 2863, 1444, 1037, 817 cm^{-1} ; MS (EI) *m/e* (%) 270.1 ($[\text{M}]^+$, 8), 252.2 (18), 237.2 (17), 165.1 (18), 142.1 (100); HRMS (EI) *m/e* calcd for $\text{C}_{18}\text{H}_{22}\text{O}_2$ $[\text{M}]^+$ 270.1620, found 270.1619.

(1*S**,2*S**,6*R**)-6-(5-*p*-Tolylpent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (1c-d). (0.133 g, 0.49 mmol, 71% from 0.174 g, 0.69 mmol of 3-(5-(*p*-tolyl)pent-4-yn-1-yl)cyclohex-2-enone). A colorless oil: ^1H NMR (400 MHz, CDCl_3) δ 7.27 (d, *J* = 8.2 Hz, 2H), 7.08 (d, *J* = 8.0 Hz, 2H), 4.00 (s, 86% D), 3.18 (s, 1H), 2.44–2.41 (m, 2H), 2.33 (s, 3H), 2.00 (br s, 1H), 1.87–1.81 (m, 1H), 1.76–1.67 (m, 5H), 1.58–1.43 (m, 3H), 1.29–1.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 137.6, 131.4, 128.9, 120.7, 88.5, 81.2, 66.4 (t, *J*_{CD} = 21.7 Hz, 1C), 63.9, 61.2, 36.5, 29.0, 26.7, 24.0, 21.4, 19.4, 18.1; ^2H NMR (76.8 MHz, CDCl_3) δ 4.00 (s, ^2H); IR (CH_2Cl_2) 3430, 3027, 2941, 2863, 1510, 1167, 818 cm^{-1} ; MS (FAB) *m/e* (%) 272.1 ($[\text{M} + \text{H}]^+$, 37), 254.1 (60), 142.1 (84), 119.1 (74); HRMS (FAB) *m/e* calcd for $\text{C}_{18}\text{H}_{22}^2\text{HO}_2$ $[\text{M} + \text{H}]^+$ 272.1761, found 272.1761.

(1*S**,2*S**,6*R**)-6-(5-(3,4-Dimethylphenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1d**). (0.600 g, 2.12 mmol, 75% from 0.750 g, 2.82 mmol of 3-(5-(3,4-dimethylphenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.17 (s, 1H), 7.12 (d, $J = 7.8$ Hz, 1H), 7.04 (d, $J = 7.7$ Hz, 1H), 4.00 (br s, 1H), 3.19 (d, $J = 3.1$ Hz, 1H), 2.44–2.41 (m, 2H), 2.24 (s, 3H), 2.22 (s, 3H), 1.94 (br s, 1H), 1.88–1.81 (m, 1H), 1.76–1.67 (m, 5H), 1.58–1.42 (m, 3H), 1.29–1.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 136.136.4, 132.6, 129.5, 128.9, 121.0, 88.3, 81.3, 66.8, 64.0, 61.2, 36.5, 29.1, 26.8, 24.0, 19.6, 19.5, 19.4, 18.1; IR (CH_2Cl_2) 3421, 2940, 2864, 1499, 1489, 1037, 820 cm^{-1} ; MS (ESI) m/e (%) 307.2 ($[\text{M} + \text{Na}]^+$, 100); HRMS (ESI) m/e calcd for $\text{C}_{19}\text{H}_{24}\text{NaO}_2$ $[\text{M} + \text{Na}]^+$ 307.1674, found 307.1677.

(1*S**,2*S**,6*R**)-6-(5-(Biphenyl-4-yl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1e**). (0.417 g, 1.25 mmol, 84% from 0.470 g, 1.5 mmol of 3-(5-([1,1'-biphenyl]-4-yl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow solid; mp 100–101 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.56 (d, $J = 7.3$ Hz, 2H), 7.51 (t, $J = 8.3$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.41 (d, $J = 7.8$ Hz, 2H), 7.33 (t, $J = 7.3$ Hz, 1H), 4.02 (br s, 1H), 3.18 (d, $J = 2.9$ Hz, 1H), 2.46–2.43 (m, 2H), 2.32 (d, $J = 7.1$ Hz, 1H), 1.86–1.79 (m, 1H), 1.76–1.68 (m, 5H), 1.59–1.42 (m, 3H), 1.28–1.20 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 140.3, 140.3, 131.9, 128.7, 127.4, 126.9, 126.8, 122.7, 90.1, 81.0, 66.9, 63.8, 61.3, 36.5, 28.9, 26.7, 24.9, 19.4, 18.3; IR (CH_2Cl_2) 2421, 3031, 2941, 1446, 842, 765 cm^{-1} ; MS (EI) m/e (%) 332.1 ($[\text{M}]^+$, 7), 314.2 (10), 204.1 (100), 191.1 (28); HRMS (EI) m/e calcd for $\text{C}_{23}\text{H}_{24}\text{O}_2$ $[\text{M}]^+$ 332.1776, found 332.1782.

(1*S**,2*S**,6*R**)-6-(5-(Naphthalen-1-yl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1f**). (0.400 g, 1.31 mmol, 83% from 0.455 g, 1.57 mmol of 3-(5-(naphthalen-1-yl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.31 (d, $J = 8.2$ Hz, 1H), 7.82 (d, $J = 8.0$ Hz, 1H), 7.77 (d, $J = 8.2$ Hz, 1H), 7.61 (d, $J = 7.1$ Hz, 1H), 7.57–7.53 (m, 1H), 7.51–7.47 (m, 1H), 7.38 (t, $J = 7.7$ Hz, 1H), 3.99 (br s, 1H), 3.20 (d, $J = 3.0$ Hz, 1H), 2.61–2.55 (m, 2H), 2.21 (br s, 1H), 1.88–1.69 (m, 6H), 1.58–1.42 (m, 3H), 1.27–1.22 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 133.3, 133.0, 129.9, 128.1, 127.9, 126.4, 126.1, 126.0, 125.4, 121.4, 94.4, 79.0, 66.9, 63.8, 61.3, 36.5, 28.7, 26.5, 24.0, 19.6, 18.3; IR (CH_2Cl_2) 3406, 2942, 2862, 2223, 1586, 1396, 801, 775 cm^{-1} ; MS (EI) m/e (%) 306.1 ($[\text{M}]^+$, 8), 178.1 (100), 165.1 (60), 141.1 (36); HRMS (EI) m/e calcd for $\text{C}_{21}\text{H}_{22}\text{O}_2$ $[\text{M}]^+$ 306.1620, found 306.1625.

(1*S**,2*S**,6*R**)-6-(5-(Phenanthren-9-yl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1g**). (0.468 g, 1.31 mmol, 66% from 0.340 g, 1.01 mmol of 3-(5-(phenanthren-9-yl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.68–8.66 (m, 1H), 8.63 (d, $J = 8.2$ Hz, 1H), 8.44–8.41 (m, 1H), 7.93 (s, 1H), 7.83 (dd, $J = 7.8$, 1.1 Hz, 1H), 7.68–7.55 (m, 4H), 4.03–4.00 (m, 1H), 3.23 (d, $J = 3.1$ Hz, 1H), 2.64–2.62 (m, 2H), 2.04 (br s, 1H), 1.92–1.72 (m, 6H), 1.59–1.44 (m, 3H), 1.30–1.25 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 131.4, 131.3, 131.3, 130.0, 130.0, 128.3 (3C), 127.1, 126.9, 126.8, 122.7, 122.5, 120.1, 94.1, 79.3, 66.9, 63.9, 61.3, 36.7, 29.0, 26.8, 24.1, 19.7, 18.1; IR (CH_2Cl_2) 3405, 3061, 2943, 2863, 2221, 1492, 1040, 892 cm^{-1} ; MS (EI) m/e (%) 356.2 ($[\text{M}]^+$, 16), 228.1 (100), 205.1 (15), 177.1 (11); HRMS (EI) m/e calcd for $\text{C}_{25}\text{H}_{24}\text{O}_2$ $[\text{M}]^+$ 356.1776, found 356.1781.

(1*S**,2*S**,6*R**)-6-(5-(3-Methoxyphenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1h**). (0.39 g, 1.36 mmol, 73% from 0.500 g, 1.86 mmol of 3-(5-(3-methoxyphenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.19 (t, $J = 7.9$ Hz, 1H), 6.98 (td, $J = 7.9$, 1.0 Hz, 1H), 6.92–6.91 (m, 1H), 6.85–6.82 (m, 1H), 4.01–3.98 (m, 1H), 3.79 (s, 3H), 3.19 (d, $J = 3.1$ Hz, 1H), 2.45–2.42 (m, 2H), 1.94 (br s, 1H), 1.88–1.80 (m, 1H), 1.76–1.67 (m, 5H), 1.53–1.43 (m, 3H), 1.31–1.25 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 159.2, 129.2, 124.7, 124.0, 116.4, 114.1, 89.3, 81.0, 66.9, 63.9, 61.2, 55.2, 36.5, 29.0, 36.7, 23.9, 19.3, 18.2; IR (CH_2Cl_2) 3402, 2940, 1578, 1288, 1044, 853 cm^{-1} ; MS (ESI) m/e (%) 309.1 ($[\text{M} + \text{Na}]^+$, 100), 244.6 (5); HRMS (ESI) m/e calcd for $\text{C}_{18}\text{H}_{22}\text{NaO}_3$ $[\text{M} + \text{Na}]^+$ 309.1467, found 309.1471.

(1*S**,2*S**,6*R**)-6-(5-(4-Methoxyphenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1i**). (0.117 g, 0.41 mmol, 45% from 0.243 g, 0.91

mmol of 3-(5-(4-methoxyphenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.33–7.30 (m, 2H), 6.82–6.79 (m, 2H), 3.99 (br s, 1H), 3.79 (s, 3H), 3.18 (d, $J = 3.0$ Hz, 1H), 2.43–2.40 (m, 2H), 2.21 (br s, 1H), 1.86–1.79 (m, 1H), 1.75–1.66 (m, 5H), 1.50–1.42 (m, 3H), 1.30–1.21 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 159.0, 132.8, 115.9, 113.8, 87.7, 80.8, 66.9, 63.9, 61.2, 55.2, 36.5, 28.9, 26.7, 24.0, 19.3, 18.2; IR (CH_2Cl_2) 3406, 3032, 2942, 2863, 1487, 842, 764, 698 cm^{-1} ; MS (FAB) m/e (%) 287.2 ($[\text{M} + \text{H}]^+$, 10), 219.2 (18), 204.1 (100), 181.1 (50), 167.1 (49); HRMS (FAB) m/e calcd for $\text{C}_{18}\text{H}_{23}\text{O}_3$ $[\text{M} + \text{H}]^+$ 287.1647, found 287.1649.

(1*R**,2*S**,6*S**)-6-(5-(4-Methoxyphenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**anti-1i**). To a solution of 3-(5-(4-methoxyphenyl)pent-4-yn-1-yl)cyclohex-2-enone and NaOH (2 M, 0.050 mL, 0.1 mmol) in methanol was added H_2O_2 (35%, 0.388 g, 4 mmol) at 0 °C, and the reaction mixture was stirred at 0 °C until the starting material is consumed (TLC). The reaction mixture was purified by flash chromatography (silica gel, 10% ethyl acetate/hexanes) affording (1*S**,6*S**)-6-(5-(4-methoxyphenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-one as a light yellow oil (0.270 g, 0.95 mmol, 95%). To a solution of (1*S**,6*S**)-6-(5-(4-methoxyphenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-one (0.227 g, 0.80 mmol) in methanol (8.0 mL) were added NaBH_4 (0.036 g, 0.96 mmol) and $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (0.417 g, 1.12 mmol) at 0 °C under air. After the reaction was stirred at room temperature for 30 min, the methanol was removed under reduced pressure. To the reaction mixture were added water and ethyl acetate (1/1). The aqueous phase was extracted with ethyl acetate (3 \times 30 mL) and washed with brine (30 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated under reduced pressure and purified by flash chromatography (silica gel, 9% ethyl acetate/hexanes) to give (1*R**,2*S**,6*S**)-6-(5-(4-methoxyphenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol as a colorless oil (0.110 g, 0.38 mmol, 48%). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.36–7.32 (m, 2H), 6.85–6.82 (m, 2H), 4.08–4.03 (m, 1H), 3.82 (s, 3H), 2.98 (s, 1H), 2.46–2.43 (m, 2H), 1.98–1.87 (m, 2H), 1.79–1.68 (m, 6H), 1.55–1.47 (m, 1H), 1.36–1.28 (m, 1H), 1.24–1.16 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 159.1, 132.9, 116.0, 113.8, 87.9, 80.8, 66.7, 62.1, 61.0, 55.3, 36.1, 30.0, 27.5, 24.1, 19.4, 15.5.

(1*S**,2*S**,6*R**)-6-(5-(2-Bromophenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1j**). (0.215 g, 0.64 mmol, 65% from 0.313 g, 0.99 mmol of 3-(5-(2-bromophenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil: $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.56 (dd, $J = 7.9$, 1.3 Hz, 1H), 7.41 (dd, $J = 7.7$, 1.8 Hz, 1H), 7.24 (td, $J = 7.9$, 1.3 Hz, 1H), 7.12 (td, $J = 7.7$, 1.7 Hz, 1H), 4.00 (br s, 1H), 3.20 (d, $J = 3.2$ Hz, 1H), 2.51–2.48 (m, 2H), 2.01–1.95 (m, 1H), 1.89–1.70 (m, 6H), 1.59–1.43 (m, 3H), 1.31–1.21 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 133.3, 132.3, 128.1, 126.9, 125.8, 125.4, 94.5, 80.0, 66.8, 63.9, 61.2, 36.4, 29.1, 26.8, 23.8, 19.5, 18.1; IR (CH_2Cl_2) 3398, 2939, 2864, 1465, 1026, 755 cm^{-1} ; MS (ESI) m/e (%) 359.0 ($[\text{M} + 2 + \text{Na}]^+$, 95), 357.0 ($[\text{M} + \text{Na}]^+$, 100); HRMS (ESI) m/e calcd for $\text{C}_{17}\text{H}_{19}\text{BrNaO}_2$ $[\text{M} + \text{Na}]^+$ 357.0466, found 357.0462.

(1*S**,2*S**,6*R**)-6-(5-(4-Bromophenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1k**). (0.372 g, 1.11 mmol, 74% from 0.432 g, 1.50 mmol of 3-(5-(4-bromophenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow solid; mp 54–55 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.41 (t, $J = 8.5$ Hz, 2H), 7.24 (d, $J = 8.4$ Hz, 2H), 4.02–3.96 (m, 1H), 3.18 (d, $J = 3.1$ Hz, 1H), 2.43–2.40 (m, 2H), 2.03–1.99 (m, 1H), 1.88–1.81 (m, 1H), 1.75–1.65 (m, 5H), 1.58–1.42 (m, 3H), 1.31–1.22 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 130.0, 131.4, 122.7, 121.7, 90.7, 80.2, 66.8, 63.8, 61.2, 36.5, 29.1, 26.8, 23.8, 19.4, 18.1; IR (CH_2Cl_2) 3406, 2942, 2863, 1711, 1486, 1070, 1010, 823 cm^{-1} ; MS (FAB) m/e (%) 335.1 ($[\text{M} + \text{H}]^+$, 35), 317.0 (60), 182.9 (85), 154.0 (100), 136.0 (72), 107.1 (39); HRMS (FAB) m/e calcd for $\text{C}_{17}\text{H}_{20}\text{BrO}_2$ $[\text{M} + \text{H}]^+$ 335.0647, found 335.0647.

(1*S**,2*S**,6*R**)-6-(5-(4-Phenylethynyl)phenyl)pent-4-ynyl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1l**). (0.844 g, 2.37 mmol, 79% from 1.014 g, 3.00 mmol of 3-(5-(4-(phenylethynyl)phenyl)pent-4-yn-1-yl)cyclohex-2-enone). A yellow oil; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.53–7.51 (m, 2H), 7.45–7.43 (m, 2H), 7.37–7.33 (m, 5H), 4.00 (br s, 1H), 3.19 (d, $J = 3.0$ Hz, 1H), 2.46–2.43 (m, 2H), 2.08 (br s, 1H),

1.88–1.84 (m, 1H), 1.75–1.67 (m, 5H), 1.59–1.43 (m, 3H), 1.31–1.22 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 131.6, 131.5, 131.4, 128.4, 128.3, 123.7, 123.1, 122.5, 91.4, 90.8, 89.1, 81.0, 66.9, 63.9, 61.2, 36.5, 29.1, 26.7, 23.9, 19.5, 18.1; IR (CH_2Cl_2) 3473, 2947, 1715, 1509, 1108, 826, 757, 692 cm^{-1} ; MS (EI) m/e (%) 356.2 ($[\text{M}]^+$, 7), 228.1 (100), 193.1 (11), 142.1 (23); HRMS (EI) m/e calcd for $\text{C}_{25}\text{H}_{24}\text{O}_2$ $[\text{M}]^+$ 356.1766, found 356.1776.

(1*S**,2*S**,6*R**)-6-(5-(4-(*p*-Tolylethynyl)phenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1m**). (0.126 g, 0.34 mmol, 71% from 0.168 g, 0.477 mmol of 3-(5-(4-(*p*-tolylethynyl)phenyl)pent-4-yn-1-yl)cyclohex-2-enone). A light yellow solid: mp 108–110 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.44–7.40 (m, 4H), 7.34 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 4.00 (br s, 1H), 3.19 (d, J = 3.1 Hz, 1H), 2.47–2.44 (m, 2H), 2.37 (s, 3H), 1.94–1.82 (m, 2H), 1.76–1.70 (m, 5H), 1.56–1.46 (m, 3H), 1.29–1.26 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 138.6, 131.5, 131.5, 131.3, 129.1, 123.5, 122.7, 120.0, 91.3, 91.1, 88.5, 81.0, 66.8, 63.9, 61.2, 36.5, 29.2, 26.8, 23.9, 21.5, 19.5, 18.0; IR (CH_2Cl_2) 3358, 2938, 2857, 1516, 1434, 1036, 839 cm^{-1} ; MS (ESI) m/e (%) 393.2 ($[\text{M} + \text{Na}]^+$, 100), 367.2 (42), 363.2 (24), 279.1 (12); HRMS (ESI) m/e calcd for $\text{C}_{26}\text{H}_{26}\text{NaO}_2$ $[\text{M} + \text{Na}]^+$ 393.1831, found 393.1834.

(1*S**,2*S**,6*R**)-6-(5-(4-(4-Methoxyphenyl)ethynyl)phenyl)pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1n**). (0.280 g, 0.73 mmol, 61% from 0.438 g, 1.19 mmol of 3-(5-(4-(4-methoxyphenyl)ethynyl)phenyl)pent-4-yn-1-yl)cyclohex-2-enone). A light yellow solid: mp 108–110 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.47–7.45 (m, 2H), 7.42 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 6.89–6.74 (m, 2H), 4.02–3.98 (m, 1H), 3.82 (s, 1H), 3.19 (d, J = 3.0 Hz, 1H), 2.46–2.43 (m, 2H), 2.09 (br s, 1H), 1.88–1.81 (m, 1H), 1.75–1.69 (m, 5H), 1.58–1.43 (m, 3H), 1.31–1.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 159.7, 133.0, 131.4, 131.2, 123.3, 122.8, 115.2, 114.0, 91.2, 90.9, 87.8, 81.0, 66.8, 63.9, 61.2, 55.3, 36.5, 29.1, 26.8, 23.9, 19.5, 18.1; IR (CH_2Cl_2) 3402, 2941, 2862, 1654, 1517, 1247, 1031, 833 cm^{-1} ; MS (ESI) m/e (%) 409.2 ($[\text{M} + \text{Na}]^+$, 100), 387.2 (11); HRMS (ESI) m/e calcd for $\text{C}_{26}\text{H}_{26}\text{O}_3\text{Na}$ $[\text{M} + \text{Na}]^+$ 409.1780, found 409.1773.

Ethyl 3-(5-((1*R**,5*S**,6*S**)-5-Hydroxy-7-oxabicyclo[4.1.0]heptan-1-yl)pent-1-yn-1-yl)benzoate (**1o**). (0.416 g, 1.27 mmol, 82% from 0.435 g, 1.40 mmol of ethyl 3-(5-(3-oxocyclohex-1-en-1-yl)pent-1-yn-1-yl)benzoate). A light yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 8.06 (t, J = 1.4 Hz, 1H), 7.94 (dt, J = 7.9, 1.3 Hz, 1H), 7.55 (dt, J = 7.9, 1.3 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 4.03–3.97 (m, 1H), 3.19 (d, J = 3.1 Hz, 1H), 2.46–2.43 (m, 2H), 2.02 (d, J = 9.6 Hz, 1H), 1.89–1.82 (m, 1H), 1.78–1.68 (m, 5H), 1.59–1.43 (m, 3H), 1.40 (t, J = 7.1 Hz, 3H), 1.32–1.23 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.0, 135.6, 132.6, 130.6, 128.6, 128.3, 124.1, 90.4, 80.3, 66.8, 63.8, 61.2, 61.1, 36.5, 29.1, 26.8, 23.8, 19.4, 18.1, 14.3; IR (CH_2Cl_2) 3424, 2941, 2863, 1720, 1295, 1227, 1105, 755 cm^{-1} ; MS (FAB) m/e (%) 329.1 ($[\text{M} + \text{H}]^+$, 43), 311.1 (100), 283.1 (97), 265.1 (53), 177.0 (65); HRMS (FAB) m/e calcd for $\text{C}_{20}\text{H}_{25}\text{O}_4$ $[\text{M} + \text{H}]^+$ 329.1753, found 329.1751.

(1*S**,2*S**,6*R**)-6-(Pent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**9**). (0.935 g, 5.19 mmol, 88% from 0.972 g, 6.00 mmol of 3-(pent-4-yn-1-yl)cyclohex-2-enone). A white oil: ^1H NMR (400 MHz, CDCl_3) δ 3.99 (br s, 1H), 3.16 (d, J = 3.0 Hz, 1H), 2.24–2.20 (m, 2H), 2.11 (br s, 1H), 1.97 (t, J = 2.6 Hz, 1H), 1.85–1.78 (m, 1H), 1.75–1.61 (m, 5H), 1.58–1.51 (m, 2H), 1.48–1.42 (m, 1H), 1.30–1.21 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 83.8, 68.8, 66.9, 63.8, 61.2, 36.3, 29.0, 26.7, 23.6, 18.4, 18.1; IR (CH_2Cl_2) 3414, 3295, 2942, 2864, 2116, 1037, 635 cm^{-1} ; MS (FAB) m/e (%) 181.1 ($[\text{M} + \text{H}]^+$, 92), 163.1 (100), 123.1 (87), 121.1 (58); HRMS (FAB) m/e calcd for $\text{C}_{11}\text{H}_{17}\text{O}_2$ $[\text{M} + \text{H}]^+$ 181.1229, found 181.1227.

(1*S**,2*S**,6*R**)-6-(Hex-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**11**). (0.579 g, 2.97 mmol, 74% from 0.705 g, 4.00 mmol of 3-(hex-4-yn-1-yl)cyclohex-2-enone). A light yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 4.01–3.97 (m, 1H), 3.16 (d, J = 3.1 Hz, 1H), 2.17–2.13 (m, 2H), 2.00 (br s, 1H), 1.85–1.79 (m, 1H), 1.77 (t, J = 2.5 Hz, 3H), 1.73–1.64 (m, 3H), 1.61–1.42 (m, 5H), 1.30–1.21 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 78.5, 76.1, 66.8, 64.0, 61.2, 36.5, 29.1, 26.7, 24.2; IR (CH_2Cl_2) 3421, 2943, 2863, 1443, 1065, 845 cm^{-1} ; MS

(APCI) m/e (%) 195.1 ($[\text{M} + \text{H}]^+$, 100), 177.1 (18); HRMS (APCI) m/e calcd for $\text{C}_{12}\text{H}_{19}\text{O}_2$ $[\text{M} + \text{H}]^+$ 195.1385, found 195.1383.

General Experimental Procedure for $\text{FeCl}_3\cdot 6\text{H}_2\text{O}$ -Catalyzed Cycloisomerization of 6-(5-Arylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ols. *Synthesis of (5*R**,6*R**,*E*)-1-Benzylidene-6-hydroxyspiro[4.5]decan-7-one (2a).* To a solution of 6-(5-phenylpent-4-yn-1-yl)-7-oxabicyclo[4.1.0]heptan-2-ol (**1a**) (0.17 g, 0.67 mmol) in DCM (67 mL) was added $\text{FeCl}_3\cdot 6\text{H}_2\text{O}$ (18 mg, 0.067 mmol) at room temperature under air. After complete consumption of the starting material (3.5 h), the reaction mixture was quenched with H_2O (50 mL). The resulting mixture was extracted with ether (3 \times 30 mL). The organic phase was dried over MgSO_4 , filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (7% ethyl acetate/hexanes) over silica gel gave **2a** (98 mg, 0.38 mmol, 57%) as a white solid: mp 116–117 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.36–7.31 (m, 4H), 7.18 (tt, J = 13.9, 1.7 Hz, 1H), 6.41 (t, J = 2.5 Hz, 1H), 4.39 (dd, J = 3.7, 1.2 Hz, 1H), 3.60 (d, J = 3.9 Hz, 1H), 2.71–2.67 (m, 2H), 2.59–2.55 (m, 1H), 2.51–2.44 (m, 1H), 2.06–2.01 (m, 1H), 1.92–1.60 (m, 6H), 1.40–1.35 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ 211.1, 150.8, 138.2, 128.5, 128.1, 126.2, 121.2, 81.3, 57.1, 39.0, 36.5, 32.3, 29.4, 24.2, 23.3; IR (CH_2Cl_2) 3475, 2946, 2831, 1714, 1108, 874, 697 cm^{-1} ; MS (EI) m/e (%) 256.2 ($[\text{M}]^+$, 65), 238.2 (46), 183.1 (100), 141.1 (68), 129.1 (28); HRMS (EI) m/e calcd for $\text{C}_{17}\text{H}_{20}\text{O}_2$ $[\text{M}]^+$ 256.1463, found 256.1465. Crystals suitable for X-ray diffraction analysis were grown from CH_2Cl_2 and hexanes.¹⁷

(5*R**,6*R**,*E*)-6-Hydroxy-1-(3-methylbenzylidene)spiro[4.5]decan-7-one (**2b**). The crude residue obtained from the reaction of **1b** (0.28 g, 1 mmol) with $\text{FeCl}_3\cdot 6\text{H}_2\text{O}$ (28 mg, 0.1 mmol) was purified by flash column chromatography to give **2b** (0.19 g, 0.70 mmol, 70%) as a yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 7.22–7.15 (m, 3H), 7.00 (d, J = 7.4 Hz, 1H), 6.38 (t, J = 2.4 Hz, 1H), 4.38 (d, J = 2.4 Hz, 1H), 3.60 (d, J = 3.7 Hz, 1H), 2.71–2.67 (m, 2H), 2.59–2.54 (m, 1H), 2.52–2.46 (m, 1H), 2.34 (s, 3H), 2.07–2.00 (m, 1H), 1.95–1.60 (m, 6H), 1.40–1.36 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 211.1, 150.5, 138.1, 137.6, 129.3, 128.0, 127.0, 125.5, 121.2, 81.3, 57.1, 39.0, 36.5, 32.3, 29.4, 24.4, 23.3, 21.5; IR (CH_2Cl_2) 3455, 2949, 2875, 1717, 144.1, 1104 cm^{-1} ; MS (APCI) m/e (%) 271.2 ($[\text{M} + \text{H}]^+$, 100), 253.2 (13); HRMS (APCI) m/e calcd for $[\text{M} + \text{H}]^+$ $\text{C}_{18}\text{H}_{23}\text{O}_2$ 271.1698, found 271.1692.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-methylbenzylidene)spiro[4.5]decan-7-one (**2c**). The crude residue obtained from the reaction of **1c** (0.14 g, 0.5 mmol) with $\text{FeCl}_3\cdot 6\text{H}_2\text{O}$ (14 mg, 0.050 mmol) was purified by flash column chromatography to give **2c** (0.10 g, 0.36 mmol, 71%) as a white solid: mp 97–99 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.25 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 6.37 (t, J = 2.4 Hz, 1H), 4.37 (s, 1H), 3.59 (d, J = 2.9 Hz, 1H), 2.67–2.65 (m, 2H), 2.58–2.54 (m, 1H), 2.50–2.42 (m, 1H), 2.33 (s, 3H), 2.04–2.00 (m, 1H), 1.90–1.60 (m, 6H), 1.39–1.35 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ 211.1, 149.7, 135.8, 135.4, 128.8, 128.4, 121.0, 81.3, 57.1, 38.9, 36.5, 32.3, 29.4, 24.4, 23.3, 21.1; IR (CH_2Cl_2) 3477, 2945, 2871, 1714, 1385, 1313, 1108, 876 cm^{-1} ; MS (EI) m/e (%) 270.2 ($[\text{M}]^+$, 70), 252.2 (21), 197.1 (100), 155.1 (51), 105.4 (68); HRMS (EI) m/e calcd for $\text{C}_{18}\text{H}_{22}\text{O}_2$ $[\text{M}]^+$ 270.1620, found 270.1617. Crystals suitable for X-ray diffraction analysis were grown from CH_2Cl_2 and hexanes.¹⁷

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-methylbenzylidene)spiro[4.5]decan-7-one (**2c-d**). The crude residue obtained from the reaction of **1c-d** (59 mg, 0.22 mmol) with $\text{FeCl}_3\cdot 6\text{H}_2\text{O}$ (5.9 mg, 0.022 mmol) was purified by flash column chromatography to give **2c-d** (48 mg, 0.18 mmol, 81%) as a white solid: mp 102–104 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.25 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 6.37 (t, J = 2.4 Hz, 86% D), 4.37 (dd, J = 3.8, 1.3 Hz, 1H), 3.59 (d, J = 3.9 Hz, 1H), 2.71–2.65 (m, 2H), 2.56–2.54 (m, 1H), 2.50–2.43 (m, 1H), 2.33 (s, 3H), 2.05–2.01 (m, 1H), 1.90–1.60 (m, 6H), 1.39–1.35 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3) δ 211.2, 149.6, 135.8, 135.4, 128.9, 128.4, 120.7 (t, $J_{\text{C-D}}$ = 23.8 Hz, 1C), 81.3, 57.1, 39.0, 36.5, 32.3, 29.4, 24.5, 23.3, 21.1; IR (CH_2Cl_2) 3476, 2944, 2871, 1714, 1107, 820 cm^{-1} ; MS (EI) m/e (%) 271.1 ($[\text{M}]^+$, 86), 253.2 (20), 242.2 (15), 198.1 (100), 156.1 (58), 106.1 (69); HRMS (EI) m/e calcd for $\text{C}_{18}\text{H}_{21}\text{HO}_2$ $[\text{M}]^+$ 271.1683, found 271.1685.

(5*R**,6*R**,*E*)-1-(3,4-Dimethylbenzylidene)-6-hydroxyspiro[4.5]decan-7-one (**2d**). The crude residue obtained from the reaction of **1d** (0.23 g, 0.85 mmol) with FeCl₃·6H₂O (23 mg, 0.085 mmol) was purified by flash column chromatography to give **2d** (0.19 g, 0.66 mmol, 80%) as a white solid: mp 108–110 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.12 (s, 1H), 7.09 (s, 2H), 6.34 (t, *J* = 2.4 Hz, 1H), 4.37 (dd, *J* = 3.8, 1.1 Hz, 1H), 3.58 (d, *J* = 3.8 Hz, 1H), 2.69–2.65 (m, 2H), 2.58–2.53 (m, 1H), 2.50–2.45 (m, 1H), 2.25 (s, 3H), 2.24 (s, 3H), 2.06–1.97 (m, 1H), 1.90–1.58 (m, 6H), 1.39–1.34 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.2, 149.5, 136.1, 135.8, 134.5, 129.9, 129.4, 125.9, 121.1, 81.3, 57.1, 39.0, 36.5, 32.3, 29.4, 24.4, 23.3, 19.8, 19.4; IR (CH₂Cl₂) 34.75, 29.42, 28.70, 1715, 1443, 1107 cm⁻¹; MS (APCI) *m/e* (%) 285.2 ([M + H]⁺, 100), 267.2 (13); HRMS (APCI) *m/e* calcd for C₁₉H₂₅O₂ [M + H]⁺ 285.1855, found 285.1849. Crystals suitable for X-ray diffraction analysis were grown from CH₂Cl₂ and hexanes.¹⁷

(5*R**,6*R**,*E*)-1-(Biphenyl-4-ylmethylene)-6-hydroxyspiro[4.5]decan-7-one (**2e**). The crude residue obtained from the reaction of **1e** (0.12 g, 0.35 mmol) with FeCl₃·6H₂O (10 mg, 0.035 mmol) was purified by flash column chromatography to give **2e** (0.09 g, 0.27 mmol, 77%) as a white solid: mp 179–180 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.61–7.56 (m, 4H), 7.44–7.40 (m, 4H), 7.34–7.32 (m, 1H), 6.43 (t, *J* = 2.2 Hz, 1H), 4.39 (d, *J* = 3.7 Hz, 1H), 3.62 (d, *J* = 3.8 Hz, 1H), 2.75–2.70 (m, 2H), 2.58–2.53 (m, 1H), 2.49–2.41 (m, 1H), 2.04–2.02 (m, 1H), 1.91–1.61 (m, 6H), 1.40–1.35 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.0, 151.1, 140.8, 138.7, 137.3, 128.9, 128.7, 127.1, 126.9, 126.7, 120.7, 81.2, 57.2, 28.9, 36.4, 32.4, 29.4, 24.4, 23.2; IR (CH₂Cl₂) 3482, 3027, 2944, 1714, 1108, 443, 699 cm⁻¹; MS (EI) *m/e* (%) 332.2 ([M]⁺, 76), 259.1 (45), 181.1 (100), 152.1 (67); HRMS (EI) *m/e* calcd for C₂₅H₂₄O₂ [M]⁺ 332.1776, found 332.1774. Crystals suitable for X-ray diffraction analysis were grown from CH₂Cl₂ and hexanes.¹⁷

(5*R**,6*R**,*E*)-6-Hydroxy-1-(naphthalen-1-ylmethylene)spiro[4.5]decan-7-one (**2f**). The crude residue obtained from the reaction of **1f** (0.15 g, 0.5 mmol) with FeCl₃·6H₂O (14 mg, 0.050 mmol) was purified by flash column chromatography to give **2f** (0.07 g, 0.23 mmol, 46%) as a white solid: mp 105–107 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.05–8.03 (m, 1H), 7.84–7.82 (m, 1H), 7.73–7.71 (m, 1H), 7.51–7.45 (m, 2H), 7.44–7.40 (m, 2H), 6.89 (s, 1H), 4.47 (s, 1H), 3.68 (br s, 1H), 2.58–2.51 (m, 1H), 2.50–2.37 (m, 3H), 2.05–1.97 (m, 2H), 1.84–1.67 (m, 4H), 1.57–1.47 (m, 1H), 1.43–1.36 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.1, 152.8, 135.4, 133.5, 131.7, 128.3, 126.8, 126.0, 125.7, 125.5, 125.2, 124.6, 118.2, 81.4, 56.3, 38.8, 36.5, 32.0, 29.5, 24.1, 23.3; IR (CH₂Cl₂) 3461, 3047, 2945, 2870, 2369, 1712, 1391, 1107, 782 cm⁻¹; MS (EI) *m/e* (%) 306.2 ([M]⁺, 100), 259.2 (13), 233.2 (70), 191.1 (55), 165.1 (61), 141.1 (58); HRMS (EI) *m/e* calcd for C₂₁H₂₂O₂ [M]⁺ 306.1620, found 306.1621.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(phenanthren-9-ylmethylene)spiro[4.5]decan-7-one (**2g**). The crude residue obtained from the reaction of **1g** (0.34 g, 0.95 mmol) with FeCl₃·6H₂O (26 mg, 0.095 mmol) was purified by flash column chromatography to give **2g** (0.15 g, 0.42 mmol, 45%) as a yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 7.9 Hz, 1H), 8.67 (d, *J* = 8.0 Hz, 1H), 8.10 (dd, *J* = 7.9, 1.0 Hz, 1H), 7.84 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.67–7.57 (m, 5H), 6.91 (t, *J* = 2.6 Hz, 1H), 4.56 (d, *J* = 3.8 Hz, 1H), 3.72 (t, *J* = 3.9 Hz, 1H), 2.64–2.50 (m, 4H), 2.61–2.08 (m, 2H), 1.94–1.74 (m, 4H), 1.60–1.44 (m, 1H), 1.48–1.42 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.1, 153.2, 140.0, 131.7, 131.3, 130.3, 129.7, 128.4, 126.7, 126.6, 126.5, 126.3, 126.2, 125.4, 122.9, 122.5, 118.6, 81.5, 56.3, 39.0, 36.6, 32.0, 29.6, 24.2, 23.4; IR (CH₂Cl₂) 3478, 3061, 2947, 2872, 1715, 1608, 1377, 1108, 898, 746 cm⁻¹; MS (APCI) *m/e* (%) 357.2 ([M + H]⁺, 100), 195.2 (57), 163.1 (22), 122.0 (18); HRMS (APCI) *m/e* calcd for [M + H]⁺ C₂₅H₂₅O₂ 357.1855, found 357.1854.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(3-methoxybenzylidene)spiro[4.5]decan-7-one (**2h**). The crude residue obtained from the reaction of **1h** (0.28 g, 0.98 mmol) with FeCl₃·6H₂O (26 mg, 0.098 mmol) was purified by flash column chromatography to give **2h** (0.16 g, 0.57 mmol, 59%) as a white solid: mp 100–102 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.24 (t, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 7.7 Hz, 1H), 6.90 (s, 1H), 6.75 (dd, *J* = 8.2, 2.4 Hz, 1H), 6.39 (t, *J* = 2.2 Hz, 1H), 4.39 (d, *J* =

3.1 Hz, 1H), 3.81 (s, 3H), 3.61 (d, *J* = 3.8 Hz, 1H), 2.72–2.68 (m, 2H), 2.60–2.55 (m, 1H), 2.52–2.47 (m, 1H), 2.07–2.02 (m, 1H), 1.92–1.60 (m, 6H), 1.41–1.36 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.1, 159.4, 151.1, 139.6, 129.0, 121.2, 121.1, 114.0, 111.9, 81.2, 57.1, 55.2, 38.9, 36.5, 32.4, 29.4, 24.4, 23.3; IR (CH₂Cl₂) 3470, 2946, 2874, 1714, 1596, 1443, 1158, 1107 cm⁻¹; MS (APCI) *m/e* (%) 287.2 ([M + H]⁺, 100), 269.2 (30); HRMS (APCI) *m/e* calcd for C₁₈H₂₃O₃ [M + H]⁺ 287.1647, found 287.1640. Crystals suitable for X-ray diffraction analysis were grown from CH₂Cl₂ and hexanes.¹⁷

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-methoxybenzylidene)spiro[4.5]decan-7-one (**2i**). The crude residue obtained from the reaction of **1i** (76 mg, 0.27 mmol) with FeCl₃·6H₂O (7.0 mg, 0.027 mmol) was purified by flash column chromatography to give **2i** (66 mg, 0.23 mmol, 86%) as a white solid: mp 90–91 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.30–7.27 (m, 2H), 6.88–6.85 (m, 2H), 6.34 (t, *J* = 2.3 Hz, 1H), 4.36 (d, *J* = 3.7 Hz, 1H), 3.80 (s, 3H), 3.60 (d, *J* = 3.8 Hz, 1H), 2.67–2.63 (m, 2H), 2.58–2.53 (m, 1H), 2.49–2.41 (m, 1H), 2.04–1.99 (m, 1H), 1.93–1.60 (m, 6H), 1.38–1.34 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.1, 157.9, 148.4, 131.0, 129.6, 120.5, 113.5, 81.2, 57.0, 55.2, 38.9, 36.5, 32.1, 29.4, 24.4, 23.2; IR (CH₂Cl₂) 3473, 2945, 1607, 1510, 1248, 1178, 1107, 1712, 1034, 827 cm⁻¹; MS (EI) *m/e* (%) 286.1 ([M]⁺, 100), 213.1 (72), 171.1 (21), 121.1 (53); HRMS (EI) *m/e* calcd for C₁₈H₂₃O₃ [M]⁺ 286.1569, found 286.1574.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(2-bromobenzylidene)spiro[4.5]decan-7-one (**2j**). The crude residue obtained from the reaction of **1j** (0.21 g, 0.63 mmol) with FeCl₃·6H₂O (17 mg, 0.063 mmol) was purified by flash column chromatography to give **2j** (27 mg, 0.08 mmol, 13%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 7.9 Hz, 1H), 7.40 (dd, *J* = 7.6, 1.0 Hz, 1H), 7.27 (t, *J* = 7.4 Hz, 1H), 7.06 (td, *J* = 7.7, 1.3 Hz, 1H), 6.57 (s, 1H), 4.41 (d, *J* = 2.8 Hz, 1H), 3.62 (d, *J* = 3.7 Hz, 1H), 2.60–2.50 (m, 2H), 2.09–1.97 (m, 2H), 1.84–1.17 (m, 4H), 1.60–1.55 (m, 1H), 1.43–1.37 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.9, 152.8, 137.8, 132.4, 129.9, 127.8, 126.9, 124.3, 120.6, 81.4, 56.8, 38.9, 36.2, 32.0, 29.3, 24.4, 23.4; IR (CH₂Cl₂) 3429, 2939, 1711, 1430, 1261, 1022, 753 cm⁻¹; MS (APCI) *m/e* (%) 377.1 ([M + H + 2]⁺, 95), 335.1 ([M + H]⁺, 100); HRMS (APCI) *m/e* calcd for C₁₇H₂₀⁷⁹BrO₂ [M + H]⁺ 335.0647, found 335.0648.

(5*R**,6*R**,*E*)-1-(4-Bromobenzylidene)-6-hydroxyspiro[4.5]decan-7-one (**2k**). The crude residue obtained from the reaction of **1k** (0.17 g, 0.5 mmol) with FeCl₃·6H₂O (13 mg, 0.050 mmol) was purified by flash column chromatography to give **2k** (28 mg, 0.08 mmol, 17%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, *J* = 8.5 Hz, 2H), 7.20 (d, *J* = 8.5 Hz, 2H), 6.34 (s, 1H), 4.36 (d, *J* = 3.8 Hz, 1H), 3.62 (d, *J* = 3.8 Hz, 1H), 2.65–2.55 (m, 3H), 2.51–2.43 (m, 1H), 2.07–2.02 (m, 1H), 1.90–1.61 (m, 6H), 1.41–1.36 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.9, 153.9, 137.2, 131.2, 130.1, 120.2, 119.9, 81.1, 57.2, 38.9, 36.4, 32.3, 29.4, 24.4, 23.2; IR (CH₂Cl₂) 3457, 2946, 2874, 1714, 1488, 1249, 1108, 1009, 824, 736 cm⁻¹; MS (EI) *m/e* (%) 334.1 ([M]⁺, 81), 318.1 (41), 261.1 (98), 182.2 (95), 165.1 (100), 141.1 (60), 128.2 (43); HRMS (EI) *m/e* calcd for C₁₇H₁₉⁷⁹BrO₂ [M]⁺ 334.0568, found 334.0564.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-(phenylethynyl)benzylidene)spiro[4.5]decan-7-one (**2l**). The crude residue obtained from the reaction of **1l** (0.14 g, 0.4 mmol) with FeCl₃·6H₂O (11 mg, 0.040 mmol) was purified by flash column chromatography to give **2l** (66 mg, 0.18 mmol, 46%) as a white solid: mp 179–181 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.57–7.50 (m, 4H), 7.37–7.35 (m, 5H), 6.42 (t, *J* = 2.3 Hz, 1H), 4.40 (d, *J* = 3.7 Hz, 1H), 3.66 (d, *J* = 3.8 Hz, 1H), 2.74–2.71 (m, 2H), 2.62–2.53 (m, 1H), 2.54–2.45 (m, 1H), 2.09–2.04 (m, 1H), 1.94–1.70 (m, 6H), 1.44–1.39 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.0, 152.1, 138.2, 131.5, 131.4, 128.4, 128.3, 128.1, 123.4, 120.8, 120.8, 89.7, 89.4, 81.2, 57.3, 38.9, 36.4, 32.5, 29.4, 24.4, 23.2; IR (CH₂Cl₂) 3477, 2945, 1714, 1385, 1313, 2871, 1108, 876 cm⁻¹; MS (EI) *m/e* (%) 356.2 ([M]⁺, 100), 283.2 (36), 241.1 (23), 191.1 (48), 141.1 (32); HRMS (EI) *m/e* calcd for C₂₅H₂₄O₂ [M]⁺ 356.1776, found 356.1776.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-(*p*-tolylethynyl)benzylidene)spiro[4.5]decan-7-one (**2m**). The crude residue obtained from the reaction of **1m** (0.11 g, 0.28 mmol) with FeCl₃·6H₂O (8.0 mg, 0.028 mmol) was purified by flash column chromatography to give **2m** (66 mg, 0.19

mmol, 62%) as a white solid: mp 170–171 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 8.2 Hz, 2H), 7.42 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.2 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 6.40 (t, *J* = 2.5 Hz, 1H), 4.39 (d, *J* = 3.7 Hz, 1H), 3.63 (d, *J* = 3.8 Hz, 1H), 2.73–2.68 (m, 2H), 2.61–2.55 (m, 1H), 2.52–2.44 (m, 1H), 2.37 (s, 3H), 2.08–2.03 (m, 1H), 1.92–1.63 (m, 6H), 1.42–1.37 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.9, 152.0, 138.3, 138.1, 131.5, 131.3, 129.1, 128.4, 121.0, 120.9, 120.3, 89.8, 89.0, 81.2, 57.3, 38.9, 36.4, 32.5, 28.4, 24.5, 23.3, 21.5; IR (CH₂Cl₂) 3455, 2943, 2866, 1712, 1516, 1342, 1107, 817 cm⁻¹; MS (ESI) *m/e* (%) 393.2 ([M + Na]⁺, 100), 360.3 (10), 266.2 (10); HRMS (EI) *m/e* calcd for C₂₆H₂₆NaO₂ [M + Na]⁺ 393.1831, found 393.1823.

(5*R**,6*R**,*E*)-6-Hydroxy-1-(4-((4-methoxyphenyl)ethynyl)benzylidene)spiro[4.5]decan-7-one (**2n**). The crude residue obtained from the reaction of **1n** (0.15 g, 0.39 mmol) with FeCl₃·6H₂O (11 mg, 0.039 mmol) was purified by flash column chromatography to give **2n** (91 mg, 0.24 mmol, 60%) as a white solid: mp 173–175 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.6 Hz, 4H), 7.32 (d, *J* = 8.3 Hz, 2H), 6.89–6.86 (m, 2H), 6.40 (t, *J* = 2.5 Hz, 1H), 4.39 (d, *J* = 3.5 Hz, 1H), 3.83 (br s, 3H), 3.63 (d, *J* = 3.6 Hz, 1H), 2.73–2.68 (m, 2H), 2.60–2.56 (m, 1H), 2.52–2.45 (m, 1H), 2.07–2.02 (m, 1H), 1.92–1.63 (m, 6H), 1.42–1.37 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.0, 159.6, 151.9, 137.9, 133.0, 131.2, 128.4, 121.2, 120.9, 115.5, 114.0, 89.6, 88.4, 81.2, 57.3, 55.3, 38.9, 36.4, 32.5, 29.4, 24.5, 23.3; IR (CH₂Cl₂) 3451, 2941, 1711, 1599, 1513, 1248, 1026, 832 cm⁻¹; MS (ESI) *m/e* (%) 409.2 ([M + Na]⁺, 700), 334.2 (40), 229.1 (70), 143.1 (60); HRMS (EI) *m/e* calcd for C₂₆H₂₆NaO₃ [M + Na]⁺ 409.1780, found 409.1783. Crystals suitable for X-ray diffraction analysis were grown from CH₂Cl₂ and hexanes.¹⁷

Ethyl 3-((*E*)-((5*R**,6*R**,*E*)-6-Hydroxy-7-oxospiro[4.5]decan-1-ylidene)methyl)-benzoate (**2o**). The crude residue obtained from the reaction of **1o** (0.11 g, 0.34 mmol) with FeCl₃·6H₂O (9.0 mg, 0.034 mmol) was purified by flash column chromatography to give **2o** (11 mg, 0.03 mmol, 10%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, 1H), 7.86 (td, *J* = 7.8, 1.3 Hz, 2H), 7.36 (d, *J* = 7.7 Hz, 1H), 7.39 (t, *J* = 7.7 Hz, 1H), 6.43 (t, *J* = 2.3 Hz, 1H), 4.47–4.35 (m, 3H), 3.64 (d, *J* = 3.8 Hz, 1H), 2.73–2.69 (m, 2H), 2.61–2.51 (m, 1H), 2.53–2.46 (m, 1H), 1.93–1.64 (m, 6H), 1.42–1.38 (m, 1H), 1.40 (t, *J* = 7.7 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 210.9, 166.7, 152.2, 138.4, 132.6, 130.4, 129.6, 128.1, 127.2, 120.4, 81.2, 60.9, 57.2, 38.9, 36.4, 32.3, 29.4, 24.4, 23.3, 14.3; IR (CH₂Cl₂) 3473, 2946, 2872, 1715, 1282, 1205, 1107, 1025 cm⁻¹; MS (EI) *m/e* (%) 328.2 ([M]⁺, 13), 299.2 (36), 253.2 (45), 149.1 (100), 141.1 (18); HRMS (EI) *m/e* calcd for C₂₀H₂₄O₄ [M]⁺ 328.1675, found 328.1678.

(1*R**,2*S**,6*S**)-8-Chlorospiro[5.5]undec-7-ene-1,2-diol (**10**). The crude residue obtained from the reaction of **9** (0.20 g, 1.13 mmol) with FeCl₃·6H₂O (30 mg, 0.11 mmol) was purified by flash column chromatography to give **10** (84 mg, 0.47 mmol, 34%) as a colorless solid: ¹H NMR (400 MHz, CDCl₃) δ 5.81 (s, 1H), 3.91–3.87 (m, 1H), 3.57 (d, *J* = 1.8 Hz, 1H), 2.30 (td, *J* = 6.4, 1.6 Hz, 2H), 2.07 (br s, 1H), 1.86–1.79 (m, 3H), 1.75–1.60 (m, 4H), 1.45–1.49 (m, 2H), 1.43–1.37 (m, 1H), 1.27–1.21 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 134.8, 128.2, 74.9, 68.9, 42.1, 33.1, 32.3, 30.2, 28.7, 19.2, 18.6; IR (CH₂Cl₂) 3421, 3301, 2942, 2866, 1713, 1647, 1449, 1059, 869, 758, 642 cm⁻¹; MS (ESI) *m/e* (%) 217.1 ([M + 2 - H]⁻, 31), 215.1 ([M - H]⁻, 100), 195.0 (11); HRMS (ESI) *m/e* calcd for C₁₁H₁₆ClO₂ [M - H]⁻ 215.0839, found 215.0832. Crystals suitable for X-ray diffraction analysis were grown from CH₂Cl₂ and hexanes.¹⁷

(5*S**,6*R**,7*S**,*Z*)-1-Ethylidenespiro[4.5]dec-2-ene-6,7-diol (**12**). The crude residue obtained from the reaction of **11** (0.39 g, 2.0 mmol) with FeCl₃·6H₂O (54 mg, 0.20 mmol) was purified by flash column chromatography to give **12** (93 mg, 0.48 mmol, 24%) and **13** (76 mg, 0.40 mmol, 20%). Compound **12** a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 5.70 (ddd, *J* = 9.9, 5.0, 2.5 Hz, 1H), 5.16–5.13 (m, 1H), 5.12–5.08 (m, 1H), 4.08–4.04 (m, 1H), 3.56 (m, 1H), 2.36–2.3 (m, 4H), 2.15–2.09 (m, 1H), 1.90 (d, *J* = 7.4 Hz, 1H), 1.81–1.75 (m, 3H), 1.58 (td, *J* = 6.4, 1.6 Hz, 3H), 1.40–1.33 (m, 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃) δ 146.9, 131.8, 124.0, 119.5, 71.5, 66.2, 54.9, 35.3, 29.3, 27.8, 21.5, 14.6; IR (CH₂Cl₂) 3421, 3301, 2942, 2866, 1713, 1647, 1449, 1059, 869, 758, 642 cm⁻¹; MS (ESI) *m/e* (%)

217.1 ([M + Na]⁺, 13), 177.1 (3); HRMS (ESI) *m/e* calcd for C₁₂H₁₈NaO₂ [M + Na]⁺ 217.1204, found 217.1200.

(5*R**,6*R**,*E*)-1-Ethylidene-6-hydroxyspiro[4.5]decan-7-one (**13**). Compound **13** a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 5.44–5.38 (m, 1H), 4.23 (dd, *J* = 3.9, 1.3 Hz, 1H), 3.56 (d, *J* = 3.9 Hz, 1H), 2.55–2.49 (m, 1H), 2.45–2.30 (m, 3H), 2.00–1.93 (m, 1H), 1.69 (dt, *J* = 6.6, 1.5 Hz, 3 H), 1.78–1.52 (m, 6H), 1.34–1.29 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 211.5, 148.4, 114.9, 81.2, 55.5, 39.0, 36.5, 30.0, 29.6, 23.5, 23.2, 14.9; IR (CH₂Cl₂) 3471, 2942, 2871, 1713, 1641, 1442, 1108, 805 cm⁻¹; MS (APCI) *m/e* (%) 195.1 ([M + H]⁺, 100), 177.1 (11); HRMS (ESI) *m/e* calcd for C₁₂H₁₉O₂ [M + H]⁺ 195.1385, found 195.1380.

■ ASSOCIATED CONTENT

Supporting Information

NMR spectra for compounds **1a–o**, **2a–o**, **2c–d**, and **9–13**, and X-ray crystallographic information files for compounds **2a**, **2c–e**, **2h**, **2n**, and **10**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: cheyeh@ntnu.edu.tw (M.-C.P.Y.).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work has been supported the by Ministry of Science and Technology (NSC 101-2113-M-003-002-MY3) and National Taiwan Normal University.

■ REFERENCES

- (1) For a recent review, see: Sannigrahi, M. *Tetrahedron* **1999**, *55*, 9007.
- (2) (a) Asaoka, M.; Takenouchi, K.; Takei, H. *Chem. Lett.* **1988**, *17*, 1225; (b) *Tetrahedron Lett.* **1993**, *34*, 3875. (c) Ficini, J.; Reviel, G.; Genêt, J. P. *Tetrahedron Lett.* **1981**, *22*, 629.
- (3) (a) Tokunaga, Y.; Yagihashi, M.; Ihara, M.; Fukumoto, K. *Chem. Commun.* **1995**, 955. (b) Brands, K. M. J.; DiMichele, L. M. *Tetrahedron Lett.* **1998**, *39*, 1677.
- (4) (a) Trost, B. M.; Lee, D. C. *J. Am. Chem. Soc.* **1988**, *110*, 6556. (b) Trost, B. M.; Chen, D. W. C. *J. Am. Chem. Soc.* **1996**, *118*, 12541.
- (5) (a) Overman, L. E. *Aldrichimica Acta* **1995**, *28*, 107. (b) Overman, L. E. *Acc. Chem. Res.* **1992**, *25*, 352. (c) Minor, K. P.; Overman, L. E. *Tetrahedron* **1997**, *53*, 8927.
- (6) (a) Tu, Y. Q.; Fan, C. A.; Ren, S. K.; Chan, A. S. C. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3791. (b) Crane, S. N.; Burnell, D. J. *J. Org. Chem.* **1998**, *63*, 5708. (c) Fujioka, H.; Kitagaki, S.; Imai, R.; Kondo, M.; Okamoto, S.; Yoshida, Y.; Akai, S.; Kita, Y. *Tetrahedron Lett.* **1995**, 3219.
- (7) (a) Marshall, J. A.; Brady, S. F. *Tetrahedron Lett.* **1969**, *10*, 1387. (b) Nagumo, S.; Suemune, H.; Saka, K. *Chem. Commun.* **1990**, 1778. (c) Janaki, S. N.; Rao, G. S. R. S. *J. Chem. Soc., Perkin Trans. 1* **1997**, 195.
- (8) (a) Marshall, J. A.; Johnson, P. C. *J. Org. Chem.* **1970**, *35*, 192. (b) Kuroda, C.; Hirono, Y. *Tetrahedron Lett.* **1994**, *35*, 6895. (c) Huang, J.; Leboeuf, D.; Frontier, A. J. *J. Am. Chem. Soc.* **2011**, *133*, 6307.
- (9) (a) Marx, J. N.; Norman, L. R. *J. Org. Chem.* **1975**, *40*, 1602. (b) Dauben, W. G.; Hart, D. J. *J. Am. Chem. Soc.* **1977**, *99*, 7307.
- (10) (a) Pagès, L.; Llebaria, A.; Camps, F.; Molins, E.; Miravittles, C.; Moreto, J. M. *J. Am. Chem. Soc.* **1992**, *114*, 10449. (b) Kondakov, D. Y.; Wang, S.; Negishi, E. *Tetrahedron Lett.* **1996**, *37*, 3803. (c) Rousseaux, S.; García-Fortanet, J.; Sanchez, M. A. D. A.; Buchwald, S. L. *J. Am. Chem. Soc.* **2011**, *133*, 9282. (d) Chai, Z.; Rainey, T. J. *J. Am. Chem. Soc.* **2012**, *134*, 3615. (e) Trost, B. M.;

Stambuli, J. P.; Silverman, S. M.; Schwörer, U. *J. Am. Chem. Soc.* **2006**, *128*, 13328.

(11) Oppolzer, W.; Mahalanabis, K. K.; Bättig, K. *Helv. Chim. Acta* **1977**, *60*, 2388.

(12) (a) Srikrishna, A.; Reddy, T. J.; Nagaraju, S.; Sattigeri, J. A. *Tetrahedron Lett.* **1994**, *35*, 7841. (b) Back, T. G.; Glastone, P. L.; Parvez, M. *J. Org. Chem.* **1996**, *61*, 3806. (c) Batey, R. A.; Harling, J. D.; Motherwell, W. B. *Tetrahedron* **1992**, *48*, 8031.

(13) For recent reviews, see: (a) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413. (b) Fürstner, A. *Angew. Chem., Int. Ed.* **2000**, *39*, 3012.

(14) Lin, M. N.; Wu, S. H.; Yeh, M. C. P. *Adv. Synth. Catal.* **2011**, *353*, 3290.

(15) Beaver, M. G.; Jamison, T. F. *Org. Lett.* **2011**, *13*, 4140.

(16) Yeh, M. C. P.; Fang, C. W.; Lin, H. H. *Org. Lett.* **2012**, *14*, 1830.

(17) CCDC 1024453 (**2a**), 1024452 (**2c**), 1024533 (**2d**), 1024457 (**2e**), 1024454 (**2h**), 1024455 (**2n**), and 1024458 (**10**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.

(18) Schegolev, A. A.; Smit, W. A.; Kucherov, V. F.; Caple, R. *J. Am. Chem. Soc.* **1975**, *97*, 6604.